Ono Competitors

Pink Sheets . USA . 
Stock . Ono Pharmaceutical Co
OPHLY Stock  USD 3.67  0.07  1.87%   
Ono Pharmaceutical competes with Santen Pharmaceutical, GSK Plc, Grifols SA, Pfizer, and Sanofi ADR; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. Analyzing Ono Pharmaceutical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Ono Pharmaceutical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Ono Pharmaceutical Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Ono Pharmaceutical competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
2.153.745.33
Details
Intrinsic
Valuation
LowRealHigh
2.434.025.61
Details
Naive
Forecast
LowNextHigh
1.993.575.16
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
3.593.854.12
Details

Ono Pharmaceutical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Ono Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Ono and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Ono Pharmaceutical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
GSK
+ 0.95
GLAXF
GSK
+ 0.95
OGN
AZN
+ 0.92
OGN
GSK
+ 0.91
SNY
SNY
+ 0.9
GLAXF
AZN
+ 0.9
GSK
  
High negative correlations   
PFE
- 0.26
GRFS
AZN
- 0.21
GRFS
RHHBY
- 0.14
GRFS
SNY
- 0.13
GRFS
GRFS
- 0.03
GLAXF
GSK
- 0.02
GRFS

Risk-Adjusted Indicators

There is a big difference between Ono Pink Sheet performing well and Ono Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ono Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
SNPHF  0.74 (0.20) 0.00 (1.37) 0.00 
 0.00 
 1.13 
(3.90)
 14.24 
GLAXF  2.04 (0.32) 0.00 (0.90) 0.00 
 0.00 
 5.20 
(5.86)
 17.25 
GRFS  1.89 (0.04)(0.05) 0.00  2.27 
(2.41)
 5.06 
(4.39)
 17.76 
PFE  0.99 (0.20) 0.00 (0.40) 0.00 
 0.00 
 2.17 
(2.45)
 8.17 
SNY  0.90 (0.22) 0.00 (2.27) 0.00 
 0.00 
 1.74 
(1.85)
 7.81 
OGN  1.50 (0.49) 0.00 (1.01) 0.00 
 0.00 
 2.62 
(3.85)
 13.38 
HZNP  0.71 (0.08) 0.00  0.26  0.00 
 0.00 
 1.13 
(0.87)
 16.07 
GSK  1.12 (0.34) 0.00 (0.96) 0.00 
 0.00 
 1.89 
(2.56)
 8.87 
AZN  1.05 (0.40) 0.00  28.98  0.00 
 0.00 
 1.28 
(3.18)
 8.50 
RHHBY  0.99 (0.22) 0.00  2.29  0.00 
 0.00 
 1.20 
(2.76)
 7.58 
All Fundamental Data

Ono Pharmaceutical Competitive Analysis

The better you understand Ono Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Ono Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Ono Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
OPHLY SNPHF GLAXF GRFS PFE SNY OGN HZNP GSK AZN
 1.87 
 3.67 
Ono
 0.88 
 10.15 
Santen
 0.72 
 16.51 
GSK
 1.15 
 8.60 
Grifols
 2.03 
 26.17 
Pfizer
 0.14 
 48.35 
Sanofi
 5.82 
 16.17 
Organon
 0.13 
 100.40 
Horizon
 0.56 
 34.15 
GlaxoSmithKline
 1.17 
 66.40 
AstraZeneca
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Not too volatile
Not too volatile
Somewhat reliable
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Below Average
Below Average
Low
Below Average
Very Small
Very Low
Dangerous
Low
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Fairly Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Buy
Buy
Strong Buy
Buy
Not Available
Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Sell
Strong Sell
Sell
Strong Hold
Cautious Hold
Cautious Hold
Not Rated
Strong Hold
Strong Hold
Current Ratio
4.16
2.48
1.43
2.68
1.59
1.3
1.58
3.96
1.43
0.81
Net Asset
739.2 B
459.98 B
60.15 B
21.45 B
226.5 B
126.46 B
12.06 B
9.11 B
59.01 B
101.12 B
Profit Margin
0.26
-0.0303
0.51
0.0231
0.0716
0.093
0.2
0.12
0.0802
0.13
EBITDA
123.45 B
53.91 B
8.8 B
1.18 B
9.56 B
12.6 B
1.44 B
1.11 B
9.08 B
12.98 B
Operating Margin
0.35
-0.0024
0.25
0.2
0.33
0.29
0.25
0.18
0.0833
0.2
Current Valuation
11.13 B
2.6 B
90.86 B
15.7 B
202.02 B
140.02 B
11.92 B
26.87 B
85.07 B
230.96 B
Price To Book
2.34
1.39
6.49
1.06
1.58
1.59
7.98
5.1
3.93
5.0
Retained Earnings
466.64 B
230.22 B
(6.55 B)
59.31 M
118.35 B
67.5 B
443 M
590.01 M
7.74 B
4.52 B
Current Asset
218.78 B
156.63 B
17.61 B
3.09 B
43.8 B
24.93 B
N/A
1.11 B
16.59 B
16.01 B
Five Year Return
1.82
1.57
5.36
2.33
3.6
3.85
N/A
N/A
5.32
2.99
Beta
0.26
0.38
0.28
0.69
0.62
0.45
0.8
1.01
0.33
0.18
Number Of Employees
3.69 K
4.32 K
45
23 K
88 K
86.09 K
10 K
2.19 K
70.21 K
89.9 K
Shares Outstanding
1.47 B
388.22 M
4.09 B
257.44 M
5.67 B
2.51 B
257.54 M
229 M
2.04 B
3.1 B
Cash Flow From Operations
61.83 B
46.04 B
7.4 B
208.28 M
8.7 B
10.26 B
799 M
1.26 B
6.77 B
10.35 B
Annual Yield
0.0208
0.0319
0.0404
N/A
0.0655
0.0422
0.0733
N/A
0.0461
0.0226
Total Debt
8.65 B
32.93 B
19.76 B
10.12 B
75.04 B
18.42 B
8.76 B
2.56 B
18.02 B
28.62 B
Return On Equity
0.16
-0.0264
0.31
0.0271
0.0454
0.0582
N/A
0.0854
0.22
0.17
Z Score
0.6
N/A
1.8
N/A
N/A
N/A
N/A
7.48
N/A
N/A
Return On Asset
0.12
-0.001
0.0659
0.0287
0.0331
0.0416
0.0791
0.0444
0.0724
0.085
Book Value Per Share
491.93
780.63
2.63
7.87
16.29
58.1
1.91
23.2
3.43
26.27
Number Of Shares Shorted
N/A
N/A
N/A
4.17 M
61.87 M
8.12 M
14.15 M
7.1 M
16.29 M
4.63 M
Current Liabilities
55.22 B
50.32 B
18.14 B
1.05 B
29.4 B
16.82 B
N/A
357.55 M
13.42 B
14.87 B
Total Asset
739.2 B
459.98 B
60.15 B
21.45 B
226.5 B
126.46 B
12.06 B
9.11 B
59.01 B
101.12 B
Debt To Equity
0.012
0.097
0.98
1.14
0.4
0.3
N/A
0.53
0.98
0.89
Last Dividend Paid
28.0
16.0
0.61
N/A
1.67
N/A
1.12
N/A
0.61
2.97
Short Ratio
N/A
N/A
N/A
7.07
1.83
4.07
6.54
2.04
3.29
1.3
Target Price
N/A
N/A
N/A
10.67
32.55
63.49
22.38
116.5
45.95
88.27
Shares Owned By Institutions
0.03
53.5
41.06
58.25
67.79
11.64
81.66
98.82
15.38
16.75
Market Capitalization
10.55 B
2.95 B
73.5 B
7.13 B
145.36 B
121.05 B
3.94 B
26.63 B
69.29 B
203.49 B
Price To Earning
18.66
14.54
11.44
14.34
9.48
7.78
4.2
32.55
11.8
103.39
Price To Earnings To Growth
N/A
20398.6
1.11
0.23
0.18
0.76
-1.75
1.0
0.73
0.71
Price To Sales
0.0303
0.0118
1.91
0.99
2.45
2.5
0.61
6.93
2.21
3.97
Net Income
80.52 B
27.22 B
14.96 B
59.31 M
2.13 B
5.4 B
1.02 B
521.48 M
4.93 B
6.9 B
Earnings Per Share
0.58
0.5
1.32
0.26
0.75
1.88
5.05
1.88
1.53
2.07
Shares Owned By Insiders
N/A
3.21
0.6
N/A
0.04
N/A
0.18
1.18
0.056
N/A
Revenue
361.36 B
266.26 B
29.32 B
6.59 B
58.5 B
46.03 B
6.26 B
3.63 B
30.33 B
45.81 B
Working Capital
163.56 B
106.3 B
(525 M)
4.14 B
(4.46 B)
6.46 B
1.59 B
2.7 B
(2.42 B)
(5.49 B)
Cash And Equivalents
136.18 B
69.53 B
6.53 B
549.09 M
2.85 B
6.9 B
706 M
2.13 B
3.72 B
4.52 B
Cash Per Share
92.88
176.84
1.62
0.4
6.44
2.76
2.14
9.4
0.32
1.46
Gross Profit
267.85 B
156.59 B
19.92 B
2.23 B
66.23 B
31.7 B
3.89 B
2.8 B
19.92 B
35.73 B
Day Typical Price
3.69
10.15
16.64
8.64
26.12
48.46
15.97
100.55
34.14
66.28
Accumulation Distribution
647.97
N/A
24.01
9660.45
1.5 M
51419.52
235683.0
0.0127
27849.67
70421.58
Market Facilitation Index
0.0
N/A
4.0E-4
N/A
N/A
N/A
N/A
1.29
N/A
N/A
Daily Balance Of Power
(0.64)
(9,223,372,036,855)
(0.30)
(0.71)
0.7324
0.1321
1.059524
0.1008
0.8261
1.084507
Period Momentum Indicator
(0.07)
(0.09)
(0.12)
(0.10)
0.52
0.07
0.89
0.13
0.19
0.77
Rate Of Daily Change
0.98
0.99
0.99
0.99
1.02
1.0
1.06
1.0
1.01
1.01
Day Median Price
3.7
10.15
16.71
8.66
26.1
48.52
15.87
100.63
34.14
66.22
Price Action Indicator
(0.06)
(0.04)
(0.26)
(0.11)
0.34
(0.13)
0.75
(0.16)
0.11
0.57
Relative Strength Index
53.1
75.08
47.27
64.77
33.21
34.4
31.34
54.53
36.78
16.76
Coefficient Of Variation
(388.55)
(1,003)
(1,095)
25785.86
(974.45)
(617.60)
(496.38)
(1,338)
(526.74)
(374.96)
Mean Deviation
1.22
0.7385
2.04
1.89
0.987
0.8982
1.5
0.7077
1.12
1.05
Jensen Alpha
(0.45)
(0.20)
(0.32)
(0.04)
(0.20)
(0.22)
(0.49)
(0.08)
(0.34)
(0.40)
Total Risk Alpha
(0.68)
(0.47)
(0.76)
(0.43)
(0.37)
(0.40)
(0.77)
(0.46)
(0.54)
(0.64)
Sortino Ratio
N/A
N/A
N/A
(0.05)
N/A
N/A
N/A
N/A
N/A
N/A
Downside Variance
N/A
N/A
N/A
5.3
N/A
N/A
N/A
N/A
N/A
N/A
Standard Deviation
1.62
1.79
3.0
2.73
1.38
1.21
2.11
1.92
1.53
1.48
Kurtosis
2.05
15.83
1.75
2.72
1.65
2.74
2.29
45.05
3.15
5.96
Potential Upside
2.41
1.13
5.2
5.06
2.17
1.74
2.62
1.13
1.89
1.28
Treynor Ratio
(1.86)
(1.37)
(0.90)
0.0017
(0.40)
(2.27)
(1.01)
0.2612
(0.96)
28.98
Maximum Drawdown
10.36
14.24
17.25
17.76
8.17
7.81
13.38
16.07
8.87
8.5
Variance
2.62
3.19
9.02
7.48
1.9
1.47
4.44
3.7
2.35
2.2
Market Risk Adjusted Performance
(1.85)
(1.36)
(0.89)
0.0117
(0.39)
(2.26)
(1.00)
0.2712
(0.95)
28.99
Risk Adjusted Performance
(0.19)
(0.07)
(0.06)
0.0102
(0.07)
(0.12)
(0.15)
(0.05)
(0.14)
(0.20)
Skewness
0.5022
(3.14)
0.223
0.5991
(0.13)
0.5331
0.3149
(5.92)
0.9933
(1.86)
Semi Deviation
N/A
N/A
N/A
2.27
N/A
N/A
N/A
N/A
N/A
N/A
Information Ratio
(0.34)
(0.17)
(0.13)
(0.04)
(0.20)
(0.27)
(0.26)
(0.14)
(0.28)
(0.35)
Value At Risk
(2.55)
(3.90)
(5.86)
(4.39)
(2.45)
(1.85)
(3.85)
(0.87)
(2.56)
(3.18)
Expected Short fall
N/A
N/A
N/A
(2.41)
N/A
N/A
N/A
N/A
N/A
N/A
Downside Deviation
N/A
N/A
N/A
2.3
N/A
N/A
N/A
N/A
N/A
N/A
Semi Variance
N/A
N/A
N/A
5.15
N/A
N/A
N/A
N/A
N/A
N/A

Ono Pharmaceutical Competition Performance Charts

Five steps to successful analysis of Ono Pharmaceutical Competition

Ono Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Ono Pharmaceutical in relation to its competition. Ono Pharmaceutical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Ono Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Ono Pharmaceutical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Ono Pharmaceutical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Ono Pharmaceutical position

In addition to having Ono Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Conservative Funds Thematic Idea Now

Conservative Funds
Conservative Funds Theme
Funds or Etfs that invest using buy-and-hold investment strategy in companies with consistent growth over many years of operation. The Conservative Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Conservative Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Ono Pink Sheet Analysis

When running Ono Pharmaceutical's price analysis, check to measure Ono Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ono Pharmaceutical is operating at the current time. Most of Ono Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Ono Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ono Pharmaceutical's price. Additionally, you may evaluate how the addition of Ono Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY